Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site)

BMC Cancer

Research

Wen Xu¹  Zeng Cao¹  Feng He²  HongLiang Yang³ 

[1] Department of Hematology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, Ti-Yuan-Bei, Huan-Hu-Xi-Road, Tianjin, People’s Republic of China;Institute of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, People’s Republic of China;Institute of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, People’s Republic of China;Department of Hematology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, Ti-Yuan-Bei, Huan-Hu-Xi-Road, Tianjin, People’s Republic of China;

关键词: Cancer of unknown primary site;    Anti-tumor;    Metastasis;    Clinical Features;    Prognosis;   

DOI  :  10.1186/s12885-022-10472-z

 received in 2022-10-18, accepted in 2022-12-21,  发布年份 2022

来源: Springer

【 摘 要 】

Cancer of unknown primary site(CUPs) is a metastatic syndrome with an unidentifiable primary tumor, even after extensive workup to seek the primary site. CUPs accounts for about 3%-5% of the total number of all cancer diagnoses worldwide. The current precision medicine era has reclassified patients with CUPs into the favorable and unfavorable prognostic subset. In this study clinical characteristics and treatment of patients of CUPs were retropactively analysed. Thirty-two patients treated from July 2016 to October 2021 were included in the Affiliated Tumor Hospital of Tianjin Medical University(Tianjin, China).Common symptoms were anemia, fever, enlarged lymph nodes, abdominal pain, edema/multiple serous cavity effusion. Patients with good prognostic factors achieved good outcomes with treatment, conversely, patients with poor prognosis were generally treated empirically and had poorer outcomes. After anti-tumor treatment, the total effective rate was 41 percent(41% was the percentage of patients who achievedtumour respons). To the end of follow-up, after anti-tumor treatment, the median Overall Survival(OS) of patients was 5.4 months.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

40798_2022_490_Article_IEq3.gif